<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The identification of patients at high risk of relapse is a critical goal of modern translational research in oncohematology </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">Minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) detection by polymerase chain reaction-based methods is routinely employed in the management of patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Current knowledge indicates that it is also a useful prognostic tool in several mature <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> and particularly in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="3" pm="."><plain>Based on this evidence clinical trials employing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>-based risk stratification are currently ongoing in FL </plain></SENT>
<SENT sid="4" pm="."><plain>In this review the 'state of the art' of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> evaluation in FL is discussed </plain></SENT>
<SENT sid="5" pm="."><plain>A short description of technical issues and recent methodological advances is provided </plain></SENT>
<SENT sid="6" pm="."><plain>Then, the bulk of the review focuses on critical take-home messages for clinicians working in the field </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, we discuss future perspectives of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection and more generally outcome prediction in FL </plain></SENT>
</text></document>